6-K 1 dp140745_6k.htm FORM 6-K

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November, 2020

 

 

Commission File Number: 001-37891 

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

X

  Form 40-F  

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes     No

X

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes     No

X

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  AC IMMUNE SA  
     
     
    By: /s/ Andrea Pfeifer  
      Name: Andrea Pfeifer  
      Title: Chief Executive Officer  



 

    By: /s/ Joerg Hornstein  
      Name: Joerg Hornstein  
      Title: Chief Financial Officer  

Date: November 13, 2020

 

2

 

EXHIBIT INDEX

 

 

Exhibit Number 

Description 

99.1 Interim Condensed Financial Statements (Unaudited) (IFRS) as of and for the three and nine months ended September 30, 2020
99.2 Management’s Discussion and Analysis of Financial Condition and Results of Operations
99.3 Press Release dated November 13, 2020

3